Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results
Articolo
Data di Pubblicazione:
2022
Abstract:
Dose-optimization strategies for biologic therapies in Crohn's disease (CD) are not well established. The SERENE CD (Study of a Novel Approach to Induction and Maintenance Dosing With Adalimumab in Patients With Moderate to Severe Crohn's Disease) trial evaluated higher vs standard adalimumab induction dosing and clinically adjusted (CA) vs therapeutic drug monitoring (TDM) maintenance strategies in patients with moderately to severely active CD.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Biologic Agent; Inflammatory Bowel Disease; Monoclonal Antibody; TNF Inhibitor
Elenco autori:
D'Haens, Geert R; Sandborn, William J; Loftus, Edward V; Hanauer, Stephen B; Schreiber, Stefan; Peyrin-Biroulet, Laurent; Panaccione, Remo; Panés, Julián; Baert, Filip; Colombel, Jean-Frederic; Ferrante, Marc; Louis, Edouard; Armuzzi, Alessandro; Zhou, Qian; Goteti, Venkata S; Mostafa, Nael M; Doan, Thao T; Petersson, Joel; Finney-Hayward, Tricia; Song, Alexandra P; Robinson, Anne M; Danese, Silvio
Link alla scheda completa:
Link al Full Text:
Pubblicato in: